221 related articles for article (PubMed ID: 36301256)
1. The Tumor Microenvironment Reprograms Immune Cells.
Cao H; Gao S; Jogani R; Sugimura R
Cell Reprogram; 2022 Dec; 24(6):343-352. PubMed ID: 36301256
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
3. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
4. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
5. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
Phuengkham H; Ren L; Shin IW; Lim YT
Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
7. Non-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy.
Zhang J; Liu S; Chen X; Xu X; Xu F
Biomed Pharmacother; 2023 Oct; 166():115336. PubMed ID: 37591126
[TBL] [Abstract][Full Text] [Related]
8. Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao Y; Shen M; Wu L; Yang H; Yao Y; Yang Q; Du J; Liu L; Li Y; Bai Y
Cell Death Dis; 2023 Sep; 14(9):587. PubMed ID: 37666813
[TBL] [Abstract][Full Text] [Related]
9. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
10. [Research Progress and New Immunotherapy Strategies of Tumor Microenvironment Metabolism].
Peng YM; Luo XM; Chen JY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):505-509. PubMed ID: 37248575
[TBL] [Abstract][Full Text] [Related]
11. The role of lipid metabolic reprogramming in tumor microenvironment.
Yang K; Wang X; Song C; He Z; Wang R; Xu Y; Jiang G; Wan Y; Mei J; Mao W
Theranostics; 2023; 13(6):1774-1808. PubMed ID: 37064872
[TBL] [Abstract][Full Text] [Related]
12. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.
Pan X; Zheng L
Cell Mol Immunol; 2020 Sep; 17(9):940-953. PubMed ID: 32699350
[TBL] [Abstract][Full Text] [Related]
14. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
Wu TN; Chen HM; Shyur LF
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948368
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
16. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications.
Fang J; Lu Y; Zheng J; Jiang X; Shen H; Shang X; Lu Y; Fu P
Cell Death Dis; 2023 Sep; 14(9):586. PubMed ID: 37666809
[TBL] [Abstract][Full Text] [Related]
17. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.
Liu K; Cui JJ; Zhan Y; Ouyang QY; Lu QS; Yang DH; Li XP; Yin JY
Mol Cancer; 2022 Apr; 21(1):98. PubMed ID: 35410257
[TBL] [Abstract][Full Text] [Related]
18. The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy.
Patwardhan MV; Mahendran R
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569686
[TBL] [Abstract][Full Text] [Related]
19. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
